UBS Group
ARQT icon

UBS Group’s Arcutis Biotherapeutics ARQT Stock Holding History

UBS Group’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$87.4M Buy
3,333,015
+3,791
+0.1% +$88.3K 0.01% 1227
2026
Q1 		$78.4M Buy
3,329,224
+85,792
+3% +$2.19M 0.01% 1232
2025
Q4 		$94.2M Buy
3,243,432
+294,994
+10% +$7.55M 0.02% 1063
2025
Q3 		$55.6M Buy
2,948,438
+10,499
+0.4% +$166K 0.01% 1520
2025
Q2 		$41.2M Buy
2,937,939
+17,931
+0.6% +$251K 0.01% 1693
2025
Q1 		$45.7M Buy
2,920,008
+130,478
+5% +$1.84M 0.01% 1559
2024
Q4 		$38.9M Buy
2,789,530
+2,569,336
+1,167% +$28.2M 0.01% 1685
2024
Q3 		$2.05M Sell
220,194
-89,377
-29% -$882K ﹤0.01% 3961
2024
Q2 		$2.88M Sell
309,571
-181,106
-37% -$1.64M ﹤0.01% 3387
2024
Q1 		$4.86M Buy
490,677
+488,577
+23,266% +$3.65M ﹤0.01% 3004
2023
Q4 		$6.78K Sell
2,100
-62,042
-97% -$169K ﹤0.01% 7672
2023
Q3 		$341K Sell
64,142
-75,610
-54% -$643K ﹤0.01% 4956
2023
Q2 		$1.33M Buy
139,752
+50,973
+57% +$566K ﹤0.01% 3960
2023
Q1 		$977K Sell
88,779
-104,532
-54% -$1.51M ﹤0.01% 4118
2022
Q4 		$2.86M Buy
193,311
+169,739
+720% +$2.97M ﹤0.01% 3023
2022
Q3 		$450K Buy
23,572
+6,853
+41% +$155K ﹤0.01% 4430
2022
Q2 		$357K Sell
16,719
-37,583
-69% -$771K ﹤0.01% 4514
2022
Q1 		$1.05M Sell
54,302
-361
-0.7% -$6.11K ﹤0.01% 4055
2021
Q4 		$1.13M Buy
54,663
+24,508
+81% +$488K ﹤0.01% 4271
2021
Q3 		$720K Buy
30,155
+18,865
+167% +$430K ﹤0.01% 4462
2021
Q2 		$309K Sell
11,290
-9,156
-45% -$258K ﹤0.01% 5070
2021
Q1 		$591K Buy
+20,446
New +$638K ﹤0.01% 4746
2020
Q4 		– Sell
-613
Closed -$18K – 8365
2020
Q3 		$18K Sell
613
-2,497
-80% -$66.7K ﹤0.01% 6376
2020
Q2 		$94K Sell
3,110
-3,358
-52% -$97K ﹤0.01% 5356
2020
Q1 		$193K Buy
+6,468
New +$174K ﹤0.01% 4749

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

UBS Group's ARQT Position: Q2 2026 in Review

UBS Group increased its Arcutis Biotherapeutics (ARQT) stake by 0.11% in Q2 2026, buying an estimated $88.3K and bringing the position to 3,333,015 shares worth $87.4M. The position accounts for 0.01% of the portfolio, ranked #1227.

UBS Group first reported a position in ARQT in Q1 2020 and has held it in 25 quarters since. The position peaked at $94.2M in Q4 2025. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • UBS Group held 3,333,015 shares of Arcutis Biotherapeutics worth $87.4M as of Q2 2026.
  • UBS Group bought 3,791 Arcutis Biotherapeutics shares in Q2 2026, an estimated $88.3K.
  • Arcutis Biotherapeutics made up 0.01% of UBS Group's portfolio in Q2 2026, its #1227 holding.
  • UBS Group first reported a position in Arcutis Biotherapeutics in Q1 2020 and has held it in 25 quarters since.
  • UBS Group's Arcutis Biotherapeutics position peaked at $94.2M in Q4 2025.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.